Health

STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/10/2026, 22:36:26 UTC.

Briefings

Roche partnered with Chinese startup Defand Therapeutics to develop molecular glue medicines for cancer and immune-driven diseases. The deal involves Defand discovering and developing multiple drugs, with an estimated total value near $1 billion. Development accelerated by data from Revolution Medicines regarding Rasonque's survival rate increase in pancreatic cancer. Financial terms remain undisclosed, with payments contingent on meeting preclinical, clinical, and regulatory goals. The partnership marks a shift in global drug development strategies.

Key points

• Roche signed a collaboration deal with Chinese startup Defand Therapeutics to develop molecular glue medicines for cancer and immune-driven diseases.
• The deal involves Defand discovering and developing multiple drugs, with an estimated total value near $1 billion contingent on meeting preclinical, clinical, and regulatory goals.

Context and limitations

Financial terms and specific preclinical, clinical, and regulatory milestones are undisclosed. Development timeline and exact number of target drugs are not specified in the evidence.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 08/10/2026, 23:00:07 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeif7qeianolxtkqhmj3gzohflhccxnubjjdvuj72exeelez5espatu